Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tadalafil in Raynaud's Phenomenon in Scleroderma
NCT01117298Phase 3Completed
- Sponsor
- Sanjay Gandhi Postgraduate Institute of Medical Sciences
- Start
- Nov 2009
- Primary completion
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Raynaud phenomenon comparing Tadalafil Arm with Placebo Arm (2 arms). Primary endpoints: Daily frequency of Raynaud's phenomenon at 8 weeks, Daily duration of Raynaud's phenomenon at 8 weeks and 2 more. Started Nov 2009; status: completed.
02
Drugs
tadalafil
03
Conditions
Raynaud phenomenon
Beyond the preview
Go deeper on NCT01117298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01117298.